Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.本發明提供對GIP、GLP-1及升糖素受體各具有活性的腸促胰島素(incretin)類似物。該等腸促胰島素類似物具有對此等受體各產生平衡活性及延長作用持續時間之結構特徵。亦提供用於治療疾病(諸如糖尿病、血脂異常、脂肪肝病、代謝症候群、非酒精性脂肪變性肝炎及肥胖症)之方法。
